Novartis (Canadian drug rights) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Novartis (Canadian drug rights) General Information

Description

Rights to develop drugs for hypertension. Fiorinal and Fiorinal C are indicated for the relief of tension-type headache whereas Visken and Viskazide are used for the treatment of mild-moderate hypertension.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 151 Steeles Avenue East
  • Milton, Ontario L9T 1Y1
  • Canada
Primary Industry
Buildings and Property
Other Industries
Other Devices and Supplies
Medical Supplies
Corporate Office
  • 151 Steeles Avenue East
  • Milton, Ontario L9T 1Y1
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novartis (Canadian drug rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novartis (Canadian drug rights)‘s full profile, request access.

Request a free trial

Novartis (Canadian drug rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novartis (Canadian drug rights)‘s full profile, request access.

Request a free trial

Novartis (Canadian drug rights) FAQs

  • Where is Novartis (Canadian drug rights) headquartered?

    Novartis (Canadian drug rights) is headquartered in Milton, Canada.

  • What industry is Novartis (Canadian drug rights) in?

    Novartis (Canadian drug rights)’s primary industry is Buildings and Property.

  • Is Novartis (Canadian drug rights) a private or public company?

    Novartis (Canadian drug rights) is a Private company.

  • What is the current valuation of Novartis (Canadian drug rights)?

    The current valuation of Novartis (Canadian drug rights) is .

  • What is Novartis (Canadian drug rights)’s current revenue?

    The current revenue for Novartis (Canadian drug rights) is .

  • Who are Novartis (Canadian drug rights)’s investors?

    Novartis has invested in Novartis (Canadian drug rights).

  • When was Novartis (Canadian drug rights) acquired?

    Novartis (Canadian drug rights) was acquired on 03-Oct-2014.

  • Who acquired Novartis (Canadian drug rights)?

    Novartis (Canadian drug rights) was acquired by Tribute Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process